Tech Titans and Pharma Gains: Palo Alto, PayPal, Eli Lilly Shine
Generated by AI AgentAinvest Market Brief
Tuesday, Aug 20, 2024 6:30 pm ET1min read
OPY--
PANW--
1. Palo Alto Networks (Nasdaq: PANW)
Palo Alto Networks surged by 7.18%. Palo Alto Networks reported an 18.19% year-over-year revenue increase to $5.838 billion and strong Q4 FY2024. Scotiabank, Oppenheimer, and JP Morgan maintain ratings of sector outperform and overweight with updated price targets of $400, $410, and $387, respectively.
2. Paypal Holdings (Nasdaq: PYPL)
Paypal Holdings gained solidly by 3.54%. PayPal Holdings reported $15.584 billion in revenue and $2.016 billion net profit for H1 2024. JP Morgan, Barclays, and Baird maintained "Overweight" ratings with price targets of $80 and $85. Daiwa Capital upgraded to "Outperform," and Argus Research upgraded to "Buy."
3. Eli Lilly Andmpany (NYSE: LLY)
Eli Lilly Andmpany gained solidly by 3.08%. Eli Lilly experienced a notable trading day on August 20 with five insider transactions disclosed. Their GLP-1 drug significantly reduces type 2 diabetes risk in prediabetic, overweight adults. Additionally, Eli Lilly expanded its Emgality commercialization agreement with Organon to 11 new markets.
Palo Alto Networks surged by 7.18%. Palo Alto Networks reported an 18.19% year-over-year revenue increase to $5.838 billion and strong Q4 FY2024. Scotiabank, Oppenheimer, and JP Morgan maintain ratings of sector outperform and overweight with updated price targets of $400, $410, and $387, respectively.
2. Paypal Holdings (Nasdaq: PYPL)
Paypal Holdings gained solidly by 3.54%. PayPal Holdings reported $15.584 billion in revenue and $2.016 billion net profit for H1 2024. JP Morgan, Barclays, and Baird maintained "Overweight" ratings with price targets of $80 and $85. Daiwa Capital upgraded to "Outperform," and Argus Research upgraded to "Buy."
3. Eli Lilly Andmpany (NYSE: LLY)
Eli Lilly Andmpany gained solidly by 3.08%. Eli Lilly experienced a notable trading day on August 20 with five insider transactions disclosed. Their GLP-1 drug significantly reduces type 2 diabetes risk in prediabetic, overweight adults. Additionally, Eli Lilly expanded its Emgality commercialization agreement with Organon to 11 new markets.
Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet